Adherens junction protein expression is associated with poor response to neoadjuvant FLOT chemotherapy and pro‐inflammatory tumor microenvironment in esophageal adenocarcinoma
Open Access
- 5 March 2026
- journal article
- Published by Wiley in International Journal of Cancer
- Vol. 159 (2) , 501-515
Abstract
Esophageal adenocarcinoma (EAC) demonstrates poor survival rates despite multimodal treatments, with significant inter‐patient variability in response to standard pre‐/perioperative therapies. This study investigates the relationship between adherens junction (AJ) protein expression in pre‐treatment biopsies and response to neoadjuvant therapies in EAC. Mass spectrometry‐based proteomics was performed on diagnostic biopsies from 157 EAC patients who subsequently received either perioperative FLOT chemotherapy or neoadjuvant CROSS radiochemotherapy. Protein expression profiles were analyzed with emphasis on AJ components. Findings were correlated with treatment response and histopathological parameters. We identified a distinct protein cluster enriched for AJ components that significantly correlated with response to FLOT chemotherapy. Among FLOT major responders, 94% exhibited high AJ expression. Low AJ expression occurred across histological subtypes, with varying frequencies: 27% in tubular‐intestinal, 40% in mixed‐type, and 50% in diffuse carcinomas. Low AJ expression was significantly associated with a pro‐inflammatory tumor microenvironment and extracellular matrix (ECM) remodeling. AJ protein expression represents a potential predictive parameter for FLOT chemotherapy response in EAC and defines distinct phenotypes. The association between reduced AJ expression and inflammatory features suggests these tumors may represent candidates for further investigation of targeted therapeutic approaches, though the role of immunotherapy in this context remains to be determined. Pre‐treatment AJ assessment could guide therapy selection to avoid ineffective therapies.Keywords
Funding Information
- Deutsche Forschungsgemeinschaft (INST 1856/71‐1 FUGG)
This publication has 51 references indexed in Scilit:
- Cell division‐dependent dissemination following E‐cadherin loss underlies initiation of diffuse‐type gastric cancerThe Journal of Pathology, 2024
- Esophageal adenocarcinoma with any component of signet ring cells portends poor prognosis and response to neoadjuvant therapyThe Journal of Thoracic and Cardiovascular Surgery, 2021
- Nanomedicine Strategies to Circumvent Intratumor Extracellular Matrix Barriers for Cancer TherapyAdvanced Healthcare Materials, 2021
- Detecting Pathological Complete Response in Esophageal Cancer after Neoadjuvant Therapy Based on Imaging Techniques: A Diagnostic Systematic Review and Meta-AnalysisJournal of Thoracic Oncology, 2019
- Inflammation and fibrosisMatrix Biology, 2018
- Biological Consequences of Radiation-induced DNA Damage: Relevance to RadiotherapyClinical Oncology, 2013
- Gap junctions and Bystander effects: Good Samaritans and executionersWiley Interdisciplinary Reviews: Membrane Transport and Signaling, 2012
- Matriptase Protects Against Experimental Colitis and Promotes Intestinal Barrier RecoveryInflammatory Bowel Diseases, 2012
- TenascinsThe International Journal of Biochemistry & Cell Biology, 2004
- Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapyCancer, 2003